Agenus | AGEN - Operating Expenses


Agenus reported $-199.08M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Celldex Therapeutics USD 649.47M 65.1M Sep/2026
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.93B 1.09B Sep/2026
Jiangsu Hengrui CNY 6.01B 449.22M Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck EUR 4.34B 249M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 133.73M 7.37M Sep/2026